Recombinant Dog Unknown protein from spot 11 of 2D-PAGE of heart tissue

Basic Research Questions

• What is the Recombinant Dog Unknown protein from spot 11 of 2D-PAGE of heart tissue?

  The Recombinant Dog Unknown protein from spot 11 of 2D-PAGE of heart tissue is a protein originally identified through two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of canine heart tissue samples. This specific protein appears as spot 11 on standard 2D-PAGE gels of canine cardiac proteins. The recombinant version of this protein is commercially available with product code CSB-BP311065DO and has been expressed using a baculovirus expression system. The protein has a sequence of "AEAAAAPAPA AAPA" and represents the full-length protein corresponding to its native form found in dog heart tissue. The protein has been assigned the Uniprot identification number P99503, indicating it has been cataloged in protein databases .

• How are proteins identified in 2D-PAGE systems of canine heart tissue?

  Protein identification in 2D-PAGE systems of canine heart tissue typically follows a multi-step process. First, heart tissue samples undergo protein extraction and solubilization. The proteins are then separated in the first dimension by isoelectric focusing (IEF) based on their isoelectric point (pI), and in the second dimension by SDS-PAGE based on molecular weight. After visualization with protein stains, individual spots of interest are excised from the gel. Identification methods include visual cross-matching with existing protein databases (such as human heart protein databases), N-terminal microsequencing analysis, and peptide mass fingerprinting. In the specific case of canine heart tissue databases, identifications for 80 protein spots have been obtained through visual cross-matching with human heart protein databases (42 spots), N-terminal microsequence analysis (25 spots), and peptide mass fingerprinting (20 spots) .

• What are the recommended storage and handling conditions for the recombinant protein?

  The recombinant dog unknown protein from spot 11 should be stored at -20°C for regular storage, or at -80°C for extended storage periods. When working with the protein, it's recommended to briefly centrifuge the vial before opening to bring contents to the bottom. The protein should be reconstituted in deionized sterile water to achieve a concentration of 0.1-1.0 mg/mL. For long-term storage after reconstitution, adding glycerol to a final concentration of 5-50% (with 50% being the default recommendation) and aliquoting before storing at -20°C/-80°C is advised. Repeated freezing and thawing should be avoided; instead, working aliquots can be stored at 4°C for up to one week. The shelf life of the protein in liquid form is approximately 6 months at -20°C/-80°C, while the lyophilized form has a longer shelf life of 12 months at the same storage temperatures .

Advanced Research Applications

• How can 2D-DIGE improve analysis of this protein compared to conventional 2D-PAGE?

  Two-dimensional difference gel electrophoresis (2D-DIGE) offers significant advantages over conventional 2D-PAGE for analyzing the unknown protein from spot 11. In 2D-DIGE, different samples are labeled with up to three different fluorescent tags before being run on the same gel, enabling direct comparison between samples (e.g., diseased vs. healthy heart tissue). This approach minimizes technical variability introduced by running separate gels, substantially improving quantification accuracy and reproducibility. The method allows for detection of subtle expression differences that might be missed with conventional 2D-PAGE. Additionally, 2D-DIGE enables better analysis of post-translational modifications that may affect the protein's function in cardiac tissue. The technique is particularly valuable for studying this protein's expression changes in various heart disease models, potentially revealing its role in cardiac pathophysiology with greater precision and statistical confidence than conventional 2D-PAGE approaches .

• What role might this protein play in canine cardiac disease models?

  While the specific function of the unknown protein from spot 11 remains to be fully characterized, proteomic databases of canine heart tissue are being actively used to study alterations in protein expression in models of heart failure and heart disease. The dog heart 2D-PAGE database containing this protein has been integrated into the HSC-2DPAGE database, which facilitates comparative studies across disease states. Research approaches typically involve comparing the expression levels of this protein between normal and diseased heart tissues to determine if it is up- or down-regulated in specific cardiac pathologies. Correlation of expression patterns with specific disease phenotypes may suggest potential functional roles. Further investigation might involve knockdown or overexpression studies in cardiac cell culture models to assess effects on cellular processes relevant to heart disease. The protein's sequence (AEAAAAPAPA AAPA) suggests it may have structural properties that could be relevant to cardiac muscle function or remodeling processes occurring during heart disease progression .

• How can this protein be investigated in the context of diet-associated dilated cardiomyopathy (DCM) in dogs?

  Investigating this protein in the context of diet-associated dilated cardiomyopathy (DCM) in dogs would require a multi-faceted approach integrating proteomics with metabolomics. Researchers should first assess whether the protein's expression levels differ in heart tissue samples from dogs with diet-associated DCM compared to healthy controls. This could be accomplished through quantitative proteomics using 2D-DIGE or mass spectrometry-based approaches. Next, correlation analyses between protein expression levels and specific dietary components identified in metabolomic profiling (such as those from pulses or legumes) could reveal potential associations. The protein could also be studied in canine cardiac cell cultures exposed to metabolites identified as elevated in DCM-associated diets, such as the 88 biochemical compounds found to be higher in 3P/FDA diets. Since diet-associated DCM shows improvement after diet change, longitudinal studies monitoring this protein's expression before and after dietary intervention would be particularly valuable. This integrative approach could help determine if this protein is involved in the pathophysiological mechanisms linking certain diets to DCM in dogs .

Experimental Design and Methodology

• What are the optimal reconstitution protocols for functional studies of this protein?

  The optimal reconstitution protocol for functional studies of the recombinant dog unknown protein from spot 11 begins with reconstituting the lyophilized protein in deionized sterile water to achieve a concentration of 0.1-1.0 mg/mL. Prior to opening the vial, it should be briefly centrifuged to ensure all protein content is at the bottom. For functional studies requiring longer-term stability, glycerol should be added to a final concentration of 5-50% (with 50% being standard practice). The specific buffer system for reconstitution may need to be optimized depending on the planned functional assay, with considerations for pH, ionic strength, and compatibility with downstream applications. For studies involving protein-protein interactions, detergents at low concentrations might be necessary to maintain solubility while preserving native interactions. Each reconstitution batch should be quality-controlled by assessing protein concentration, purity (>85% by SDS-PAGE), and functional activity through appropriate binding or activity assays. All reconstituted protein should be divided into single-use aliquots to avoid freeze-thaw cycles that could compromise protein integrity .

• How can researchers design experiments to study protein-protein interactions involving this unknown protein?

  Designing experiments to study protein-protein interactions involving the unknown protein from spot 11 requires a systematic approach utilizing complementary techniques. Initially, researchers should conduct pull-down assays using the recombinant protein as bait to identify potential binding partners in canine cardiac lysates. This can be followed by co-immunoprecipitation studies to confirm interactions in more physiological contexts. Yeast two-hybrid screening offers another approach for discovering novel interacting proteins. For detailed characterization of confirmed interactions, surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) can provide quantitative binding parameters such as association/dissociation constants.

  Researchers should also consider proximity-based labeling methods such as BioID or APEX, where the unknown protein is fused to a biotin ligase or peroxidase to biotinylate proteins in close proximity within living cells. Cellular localization studies using fluorescently tagged versions of the protein can provide contextual information about where these interactions might occur physiologically. Finally, functional validation through co-expression or knockdown studies in relevant cell models (e.g., canine cardiac myocytes) should be performed to establish the biological significance of identified interactions. Throughout these studies, appropriate controls including non-specific proteins with similar physicochemical properties should be included to distinguish specific from non-specific interactions .

• What considerations should guide sample preparation for 2D-PAGE analysis of this protein in different disease states?

  Sample preparation for 2D-PAGE analysis of the unknown protein from spot 11 across different canine cardiac disease states requires careful consideration of several factors to ensure reliable and reproducible results. First, tissue sampling must be consistent, with samples collected from the same cardiac region (e.g., left ventricle) and rapidly preserved to prevent proteolytic degradation. Flash-freezing in liquid nitrogen followed by storage at -80°C is recommended. Protein extraction should use buffers optimized for cardiac tissue, typically containing chaotropic agents (urea/thiourea), reducing agents, detergents, and protease/phosphatase inhibitors.

  Sample normalization is critical—protein concentration should be standardized across all samples using Bradford or BCA assays. For disease comparison studies, matched controls are essential, with animals of similar age, sex, and breed to minimize biological variability. Technical replication (multiple gels per sample) and biological replication (multiple animals per condition) are necessary for statistical validity. When focusing specifically on the spot 11 protein, preliminary studies to establish its typical migration position and appearance characteristics under standard conditions should be conducted. This creates a reference point for identifying alterations in disease states. Finally, researchers should consider using 2D-DIGE rather than traditional 2D-PAGE when possible, as the ability to run control and disease samples on the same gel significantly reduces technical variability .

Integration with Advanced Research Techniques

• How can mass spectrometry complement 2D-PAGE studies of this protein?

  Mass spectrometry (MS) provides powerful complementary approaches to 2D-PAGE studies of the unknown protein from spot 11, enhancing both identification confidence and functional characterization. After spot identification on 2D gels, the protein can be excised, digested with trypsin, and analyzed by peptide mass fingerprinting using MALDI-TOF MS or more complex LC-MS/MS methods. This approach generates a peptide fingerprint that can be compared against protein databases for definitive identification and sequence validation beyond the reported "AEAAAAPAPA AAPA" sequence.

  MS can also identify post-translational modifications (PTMs) that may be crucial to the protein's function but invisible on 2D gels. Targeted MS approaches like multiple reaction monitoring (MRM) or parallel reaction monitoring (PRM) allow absolute quantification of the protein across different samples with greater sensitivity than gel-based methods. For comprehensive characterization, top-down proteomics using intact protein MS can reveal proteoforms with different PTM combinations.

  Integration of MS with immunoprecipitation (IP-MS) can identify protein interaction partners, while cross-linking MS (XL-MS) can map structural relationships between interacting proteins. Finally, spatial proteomics using laser capture microdissection coupled with MS can determine the protein's distribution across different cardiac tissue regions, potentially revealing localized functions relevant to cardiac physiology or pathology .

• What approaches can be used to study the functional significance of this protein in canine heart disease?

  Studying the functional significance of the unknown protein from spot 11 in canine heart disease requires a multi-dimensional approach spanning molecular, cellular, and in vivo systems. At the molecular level, gene editing techniques such as CRISPR/Cas9 can be employed in canine cardiac cell lines to generate knockout or knockdown models, enabling assessment of cellular phenotypes when the protein is absent or reduced. Complementary overexpression studies using viral vectors can determine effects of protein abundance on cellular processes relevant to heart disease, such as hypertrophy, contractility, or metabolism.

  Primary canine cardiomyocytes or induced pluripotent stem cell (iPSC)-derived cardiac cells can serve as physiologically relevant platforms for functional studies. In these systems, researchers can assess the protein's impact on calcium handling, contractile properties, mitochondrial function, and response to stress stimuli mimicking heart disease conditions. The protein's role in cell signaling pathways can be investigated through phosphoproteomic analyses following manipulations of protein expression.

  For translational significance, collaborative studies with veterinary cardiologists can correlate the protein's expression levels in endomyocardial biopsies with disease severity, progression, and treatment response in clinical cases. Finally, development of specific inhibitors or activators of the protein based on its structure could provide therapeutic proof-of-concept if the protein is determined to play a causative role in cardiac pathology .

Data Analysis and Bioinformatics

• What bioinformatic tools can help predict the function of this uncharacterized protein?

  Multiple bioinformatic approaches can help predict the function of the unknown protein from spot 11. Sequence-based tools include BLAST for identifying homologous proteins across species, while multiple sequence alignment tools like Clustal Omega can reveal evolutionarily conserved regions suggesting functional importance. Motif recognition software (PROSITE, Pfam) can identify functional domains, while software like SignalP or TMHMM can predict cellular localization signals.

  Structure prediction tools such as AlphaFold2 or I-TASSER can generate 3D structural models based on the protein's sequence, which can then be analyzed for structural similarity to known proteins using DALI or TM-align. Molecular docking simulations can predict potential binding partners or substrates.

  Functional association networks can be constructed using tools like STRING or GeneMANIA, incorporating data from experimental protein-protein interactions, co-expression analyses, and shared functional annotations. Gene Ontology enrichment analysis of these networks can suggest biological processes the protein might participate in.

  For canine-specific predictions, the comparative analysis can be enhanced by examining the protein's expression pattern across different tissues in canine transcriptomic datasets, and by leveraging orthology relationships with better-characterized proteins in model organisms. Finally, tools like NetPhos or UbPred can predict post-translational modification sites that might regulate the protein's activity or localization in cardiac tissue .

• How can researchers integrate proteomic data on this protein with other molecular datasets?

  Integrating proteomic data on the unknown protein from spot 11 with other molecular datasets requires a multi-omics approach. First, researchers should correlate the protein's expression levels with transcriptomic data from the same samples to determine if regulation occurs at transcriptional or post-transcriptional levels. This can be accomplished by extracting both protein and RNA from matched samples and performing parallel 2D-DIGE/mass spectrometry and RNA-seq analyses.

  Integration with metabolomic data is particularly relevant in the context of diet-associated cardiac diseases. Correlation analyses between the protein's abundance and specific metabolites can reveal potential functional relationships, as demonstrated in studies of diet-associated DCM where 88 named biochemical compounds were identified as elevated in disease-associated diets. Pathway enrichment analyses incorporating both proteomic and metabolomic data can identify biological processes potentially involving this protein.

  For clinical relevance, integration with phenotypic data from canine patients is essential. This includes correlating protein expression with echocardiographic parameters, cardiac biomarkers, or clinical outcomes. Longitudinal studies can assess how the protein's levels change in response to interventions like dietary changes in DCM cases.

  Data integration platforms such as Cytoscape or specialized multi-omics analysis tools can visualize and analyze relationships across these diverse datasets. Finally, the findings can be contextualized within the broader knowledge of cardiac physiology using systems biology approaches that incorporate existing pathway databases such as KEGG or Reactome .

Research Applications and Future Directions

• How might this protein be utilized in developing canine cardiac disease models?

  The unknown protein from spot 11 could serve as a valuable molecular marker or therapeutic target in developing improved canine cardiac disease models. If expression analysis across multiple studies confirms consistent up- or down-regulation of this protein in specific cardiac pathologies, it could be developed as a biomarker for early disease detection or monitoring treatment response. Genetically modified canine cardiac cell lines with altered expression of this protein could serve as in vitro disease models for high-throughput drug screening.

  For in vivo applications, cardiac-specific overexpression or knockdown of this protein in laboratory animals could determine if alterations in its expression are sufficient to induce or ameliorate cardiac pathology. While genetic modification of dogs raises ethical concerns, techniques like adeno-associated virus (AAV)-mediated gene delivery could achieve temporary modification of protein expression in specific cardiac regions.

  The protein could also be incorporated into tissue engineering approaches, where its presence or absence in engineered cardiac tissues might influence functional properties in ways that better recapitulate disease phenotypes. Finally, if the protein proves to have immunogenic properties, development of antibodies against it could enable immunohistochemical studies across different cardiac pathologies and potentially lead to imaging approaches for non-invasive visualization of cardiac remodeling processes .

• What potential exists for using this protein in comparative studies across species?

  The unknown protein from spot 11 presents significant opportunities for comparative studies across species, potentially revealing evolutionary conservation of cardiac molecular pathways. Cross-species comparison should begin with identifying orthologs through sequence similarity searches in standard protein databases. The 14-amino acid sequence (AEAAAAPAPA AAPA) can serve as the starting point, though full protein characterization may reveal this is only a fragment of a larger protein.

  Sequence conservation analysis across mammals can determine if this protein is dog-specific or more broadly conserved, potentially indicating its fundamental importance in cardiac function. Structural comparisons using techniques like X-ray crystallography or cryo-EM across species variants could reveal conserved structural motifs despite potential sequence divergence.

  Functional studies comparing the protein's role in primary cardiomyocytes from different species (canine, murine, human) would establish whether its cellular function is conserved. This is particularly relevant as dogs are considered excellent models for human cardiac diseases due to similar heart sizes, hemodynamics, and disease presentations.

  The protein's expression in response to cardiac stressors (like pressure overload or ischemia) could be compared across species to determine if it participates in conserved stress response pathways. Finally, if disease associations are established in dogs, targeted studies in human cardiac tissues could assess whether the human ortholog has similar disease associations, potentially identifying new targets for human cardiac therapies .